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Abstract: (Macro)-autophagy is a homeostatic process by which eukaryotic cells dispose of 
protein aggregates and damaged organelles. Autophagy is also used to degrade  
micro-organisms that invade intracellularly in a process termed xenophagy. Genome-wide 
association scans have recently identified autophagy genes as conferring susceptibility to 
???????? ???????? ?????? ???? ??? ??? chronic inflammatory bowel diseases, with evidence 
suggesting that CD arises from a defective innate immune response to enteric bacteria. Here 
we review the emerging role of autophagy in CD, with particular focus on xenophagy and 
enteric E. coli strains with an adherent and invasive phenotype that have been consistently 
isolated from CD patients with ileal disease. 
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1. Introduction 
???????? ???????? ?????? ???? ??? ?????????? ?????? ??? ????????????? ?????? ???????? ??????? ??? ?? ????????
disease of the intestinal tract associated with significant morbidity [1]. CD may occur anywhere in the 
gastrointestinal tract with discontinuous transmural inflammation, commonly affecting the terminal 
ileum (distal small bowel) in adults, but with more extensive and often panenteric involvement in 
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children [2]. The exact etiological factors involved in IBD aetiopathogenesis remain elusive; however it 
is clear that genetic predisposition [3], environmental influences [4] and a dysregulated immune 
response to the intestinal microflora are involved [5]. Major CD susceptibility pathways uncovered 
through recent genome-wide association studies (GWAS; the examination of many common genetic 
variants in different individuals to determine any association with a trait) implicate the innate immune 
response (e.g., NOD2), the more specific, acquired T cell response (e.g., IL23R, ICOSLG) and more 
recently autophagy (e.g., ATG16L1, IRGM) [3,6]. Examination of the disease-associated microbiome 
has also alluded to several potentially contributory organisms, most notably adherent-invasive  
E. coli strains (AIEC), which have been isolated by independent investigators in both adult [7] and 
paediatric [8] CD patients. This review will discuss the emerging role of autophagy in CD, with 
particular focus on enteric E. coli strains with an adherent and invasive phenotype (AIEC). 
2. (Macro)-Autophagy  
Two cellular processes, the ubiquitin-proteasome pathway and autophagy are involved in the 
removal of redundant, misfolded and harmful proteins [9,10]. Unlike the proteasome, autophagy can 
target large protein aggregates and also has the ability to degrade deoxyribonucleic acid (DNA), 
ribonucleic acid (RNA) and lipids [11]. Ultimately all autophagic pathways converge at the lysosome, a 
central, acidic organelle that harbours lysosomal hydrolases such as peptidases and nucleases [12]. 
Three major types of autophagic mechanisms have been described in mammalian cells, namely 
chaperone-mediated autophagy (CMA), microautophagy and macroautophagy. CMA is estimated to 
degrade approximately 30% of cytosolic proteins, specifically targeting proteins bearing a motif in their 
amino acid sequence biochemically related to the pentapeptide KEFRQ [13]. This pathway is mediated 
by heat shock cognate 70 and degradation occurs following interaction with lysosomal-associated 
membrane protein 2 [14]. Microautophagy refers to the direct engulfment of the cytoplasm by the 
lysosome [15]. This process has been shown to occur in five main stages, namely microautophagic 
invagination, followed by vesicle formation, expansion, scission and degradation [15]. Although 
discovered in the 1960s [16], many of the mechanisms involved in microautophagy are still unclear and 
its role in disease is still to be determined. Although several other forms of autophagy are now being 
investigated [15], it is the process of macroautophagy which has gained most attention in the field of 
disease pathogenesis [17]. Macroautophagy (hereafter referred to as autophagy) differs from CMA and 
microautophagy in that it relies on specialised double membrane vesicles called autophagosomes that 
form de novo through the assembly of protein and lipid constituents. Enigmatic for many years, it is now 
clear that autophagosomes originate from the surface of membranes of various cell organelles, including 
the endoplasmic reticulum, mitochondria and the plasma membrane [18]. Autophagy is upregulated in 
response to many stimuli including starvation, genotoxic stress and microbial infection [19].  
The process of autophagy is controlled by the ATG proteins (or autophagy-related proteins) and can 
be divided into three distinct stages: vesicle nucleation, vesicle elongation and fusion of the 
autophagosome with a lysosome (Figure 1). 
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Figure 1. Schematic representation of autophagy. An expanding membrane sac (the 
phagophore) sequesters cytosolic material forming a double membrane vesicle (the 
autophagosome) enclosing proteins, organelles or pathogens to be degraded. The 
autophagosome then fuses with the acidic lysosome forming the final autophagolysosome. 
 
The further detailed and complex molecular machinery involved in autophagosome formation is 
outwith the scope of this focussed review, however a summary of the major pathways are outlined in 
Figure 2 and discussed comprehensively in several excellent articles [17,20,21]. 
Figure 2. Molecular machinery of autophagosome formation. Two ubiquitin-like protein 
conjugation systems (the LC3/ATG8 and ATG12 systems) mediate membrane formation 
and expansion. PE, phosphatidylethanolamine; G, glycine. 
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3. Antimicrobial Autophagy (Xenophagy) 
Autophagy is activated in response to diverse stress or stimuli, including infection and is a crucial 
part of the innate immune defence against micro-organisms [22]. Antimicrobial autophagy, also referred 
to as xenophagy can selectively target microbes, including virus, protozoa and bacteria for degradation 
in lysosomes [22]. Host cell defence against infection is complex and involves the convergence of 
several pathways. Pathogens invading host cells are initially detected by pattern recognition receptors 
(PRR), which include Toll-like receptors (TLR) on the surface of cells and interior of endosomes, and 
cytosolic NOD-like receptors (NLR). PRRs detect the presence of microbes through specific  
microbe-associated molecular patterns (MAMPs) such as peptidoglycan and lipopolysaccharide which 
are major constituents of bacterial cell walls [23]. The recognition of MAMPs by PRRs triggers the 
activation of several signalling cascades, among them NF-?B an important regulator of inflammatory 
cytokine production, as well as antimicrobial mechanisms to clear the infection. Mounting evidence 
supports a role for autophagy as an antimicrobial mechanism downstream of TLR and NLR signalling. 
For example, stimulation of NOD2 by muramyldipeptide (MDP), a constituent of peptidoglycan, 
induces autophagy in dendritic cells in a receptor-interacting serine-threonine kinase 2 (RIPK-2) 
dependent manner [24] and discussed in detail in a later section of this review, while stimulation of 
TLR2, 4 and 7 with their specific ligands has also been shown to stimulate autophagy [25,26]. In 
addition to its essential role in innate immune defence against infection, autophagy plays a role in the 
adaptive immune response. Autophagosomes can deliver pathogen protein fragments (peptides) to 
MHC class II molecules. Once the MHC class II molecule is bound to the pathogen fragment it is 
transported to the surface of the cell where it triggers an appropriate CD4+ T-cell response [27]. 
Recently, cargo receptor proteins or adaptors such as p62/SQSTM, NBR1 and NPD52 that contain 
both ubiquitin-binding and LC3-binding domains have been shown to detect intracellular bacteria [28]. 
Bacteria are heavily ubiquitinated in the host cell cytosol [29], therefore by simultaneously binding to 
ubiquitinated cargo and LC3-containing autophagosomes, cargo receptors can target invading microbes 
to lysosomes for degradation. For example, p62 and NPD52 have recently been shown to target the 
intracellular pathogen Salmonella typhimurium to the autophagic machinery [30]. Additionally, recent 
work has demonstrated that phosphorylation of the autophagy receptor optineurin by protein kinase 
TANK binding kinase 1 (TBK1) enhanced the LC3 binding affinity and autophagic clearance of 
ubiquitin-coated cytosolic Salmonella enterica [31]. While it is clear that both PRRs and cargo 
receptors contribute to the detection and elimination of cytosolic bacteria via autophagy, it remains to 
be determined how these factors functionally interconnect and whether they constitute a general  
anti-microbial defence mechanism or a more specific defence against pathogens. 
4. Genetic Variants in Autophagy Pathway Genes and Crohn?s Disease Susceptibility  
Before discussing the autophagy-related proteins implicated in CD aetiopathogenesis it is first 
important to recognise the genetic research that ignited the current interest in autophagy within the 
study of IBD. The first study to link the autophagy pathway with CD pathogenesis was a GWAS by 
Hampe et al. carried out in 2007 [32]. Using 735 CD patients and 368 controls, single nucleotide 
polymorphisms (SNPs) with a p value < 0.01 were followed up in three independent cohorts. This 
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revealed a disease association with SNP rs2241880 in the autophagy-related 16-like 1 (ATG16L1) gene 
on chromosome 2q37.1. Resequencing of exons, splice sites and promotor regions concluded that the 
entire association signal was likely due to this threonine to alanine substitution (Thr300Ala or T300A), 
however very recent data has suggested additional variants, independent of rs2241880, could implicate 
any of the coiled-coil domain, the WD (tryptophan-aspartic acid, Trp-Asp or WD40 repeat) domain 
and/or the 3' untranslated region, in CD susceptibility [33]. Almost immediately following this initial 
finding, confirmation of this association was published by the same group in an independent cohort [34] 
and within 12 months multiple research groups had replicated the discovery in a variety of cohorts both 
in Europe and further afield [35?39]. Subsequently further individual genetic association studies have 
confirmed this finding in Caucasian populations [40], in addition to validation by several  
meta-analyses [41,42]. However replication in Asian populations has not been forthcoming despite 
various attempts [42?45]. Interestingly several paediatric studies have sought to confirm the association 
in childhood-onset CD however results have been conflicting, with two smaller studies confirming the 
association [46,47] while two larger studies proved negative [48,49], possibly reflecting the strong 
association with ileal Crohn?s disease (a phenotype not as common in childhood-onset disease [2]).  
Another gene on chromosome 5q33.1, immunity-related GTPase family, M (IRGM), was linked with 
CD susceptibility through a genome-wide association scan by the Wellcome Trust Case Control 
Consortium (WTCCC), again in 2007 [37]. In a case-control study involving 1748 CD patients and 
2938 controls, SNPs achieving a p value < 10?5 (below the stringent threshold of their original study 
that incorporated several major diseases [50]) were followed up. Using a new panel of over a thousand 
Caucasian CD patients, allele frequency comparisons were made between CD cases and nearly six 
thousand non-autoimmune WTCCC cases (which included patients with bipolar disorder, coronary 
artery disease and hypertension) as well as independent population controls from the 1958 British Birth 
Cohort. The strongest replication adjacent to a known gene was for SNPs rs13361189 and rs4958847 
immediately flanking the IRGM gene on chromosome 5. Resequencing of IRGM in 48 CD patients 
revealed three novel SNPs which were subsequently genotyped in an independent case-control cohort. 
This demonstrated that only the silent 313T > C variant was associated with CD. This SNP was in 
strong linkage disequilibrium with the original rs13361189 suggesting that the causal variant may lie in a 
regulatory region adjacent to IRGM thus affecting transcription. Since this initial finding, the association 
of SNPs in IRGM have been replicated in other adult CD populations [41,51,52], but again not in  
early-onset cohorts [53,54]. 
A subsequent meta-analysis of three GWAS with 3230 adult CD cases and 4829 controls demonstrated 
that the A allele of a SNP on chromosome 12q12 (rs11564258) was over-represented in CD patients, 
tagging a 0.89 Mb region containing both Leucine-rich repeat serine/threonine protein kinase 2 
(LRRK2) and mucin 19, oligomeric (MUC19) [41]; this was later replicated in a paediatric GWAS [54]. 
Although the susceptibility gene at this locus has been shown to be most likely LRRK2 (rather than 
MUC19) [55], replication in subsequent individual studies has been inconsistent [56,57]. A further SNP 
(rs2412973) at locus 22q12 has shown association with childhood-onset CD patients [54]. With regards 
to colonic expression, the only gene in this region which was shown to differ between the two major 
IBD types (CD and ulcerative colitis) and healthy controls was myotubularin-related protein 3 
(MTMR3). This gene showed significantly reduced expression in colonic biopsies in UC patients 
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compared to controls and was also significantly associated with CD in the meta-analysis of discovery 
and replication cohorts. To date there have been no attempts to replicate this finding in either adult or 
paediatric populations. 
Along with the original discovery of ATG16L1 variants, SNPs in the region of protein tyrosine 
phosphatase, non-receptor type 2 (PTPN2) were also described [37]. This was again replicated in 
several populations, including paediatric cohorts [58?60]. Genetic association studies have also 
identified SNPs in unc-51-like kinase 1 (ULK1) [61,62], with conflicting results with regard to the 
association of variations in neutrophil cytosolic factor 4 (NCF4) [35,63,64]. 
5. Autophagy Proteins Implicated in Crohn?s Disease Pathogenesis  
5.1. ATG16L1 and NOD2 
Following the initial identification and confirmation of ATG16L1 as a CD susceptibility gene  
in 2007 [32,35,36], and its relationship with an ileal disease phenotype [34], further studies began to 
unravel the potential biological relevance to this protein in CD pathogenesis. ATG16L1 is a member of 
a large group of ATG and ATG-related proteins which are intimately involved in autophagosome  
biogenesis [65]. Along with ATG12 and ATG5, ATG16L1 forms a 800 kDa complex in a 2:2:2 
stoichiometry; although this ATG12 system has no deconjugating enzyme, the complex is formed 
constitutively irrespective of nutrient conditions [65,66]. During autophagosome formation the complex 
localises to the outer surface of the isolation membrane and dissociates following completion of the 
autophagosome [67].  
One of the first studies that began to outline the precise functional role of ATG16L1 was by  
Fujita et al. [66]. Using a variety of mammalian cell culture techniques they demonstrated that the 
ATG12-ATG8-ATG16L1 complex was involved in LC3-lipidation, and interestingly that overexpression of 
ATG16L1 (specifically the coiled-coil region) disrupted the subunit stoichiometry leading to reduced 
autophagy. Also, the importance of correct localisation of ATG16L1 to sites of LC3-lipidation (such as 
the plasma membrane) was also shown to be vital for appropriate autophagosome formation. The same 
group later described the interaction of the Golgi-resident GTPase Rab33B with ATG16L1, however 
the precise pathways involved during autophagy are still to be determined [68]. More relevant to CD 
pathogenesis, Saitoh et al. demonstrated that ATG16L1-deficient macrophages produced high amounts 
of the inflammatory cytokines interleukin 1-beta (IL-???? ???? ???????????-18 (IL-18) following 
stimulation with the Toll-like receptor 4 (TLR4) ligand lipopolysaccharide (LPS) [69]. They also 
showed that this increased IL-?? production was due to Toll/IL-1 receptor domain-containing adaptor 
inducing IFN-? (TRIF)-dependent activation of caspase-1 in ATG16L1-deficient cells. Additionally they 
utilised mice with ATG16L1-deficient haematopoetic cells to highlight their increased susceptibility to 
dextran sulphate sodium-induced colitis, which was in turn alleviated by treatment with IL-??? ???? 
IL-18 antibodies.  
Cadwell et al. extended this work by initially generating mice and murine embryonic fibroblasts that 
were hypomorphic for ATG16L1 (using gene trap-mediated disruptions of ATG16L1) [70]. Using this 
method allowed the detailed investigation of the consequences of low-expressing ATG16L1, avoiding 
the lethal effect of gene deletion [71,72]. They demonstrated that rapamycin-induced degradation of the 
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adaptor protein p62 and LC3-II was diminished in ATG16L1 hypomorphic fibroblasts, which was 
restored by expressing ATG16L1. Additionally they showed that hypomorphic mice expressed 
approximately 25% of the expected levels of ATG16L1 in their ileum which equated to an increase in 
LC3-I:LC3-II ratio and p62. However, more importantly, these mice also showed striking abnormalities 
in Paneth cell morphology (Paneth cells are felt to be a key site in CD pathogenesis [73]) including lack 
of mucal lysozyme staining, reduced and disorganised granules, degenerating mitochondria and absence 
of apical microvilli. Following this, these changes in Paneth cell biology were confirmed in ileocolic 
resection specimens from CD patients carrying the ATG16L1 risk allele. Overall these data provided the 
first indication that ATG16L1 had a specific role in humans and mice in regulating the specialised 
properties of Paneth cells. 
In 2010 there were several publications which intriguingly brought together two of the  
major pathways implicated in CD pathogenesis, namely the innate response (through NOD2) and  
autophagy. ???????????? ???????????????????????????????-line, non-specific response to foreign antigen. 
Both transmembrane and intracellular pattern recognition receptors (PRRs) recognise conserved, 
microbe-specific molecules named pathogen-associated molecular patterns (PAMPs; also known as 
microbe-associated molecular patterns (MAMPs)) such as LPS and peptidoglycan, leading to an 
appropriate immune response [23]. The NLR family are a major group of PRRs with a characteristic 
domain architecture comprising a central nucleotide binding and oligomerisation domain (NOD), an  
N-terminal effector binding (CARD) domain and C-terminal leucine-rich repeats (LRR) through which 
they detect MAMPs [74]. A key breakthrough in both CD and complex disease pathogenesis came 
in 2001 when fine mapping of the IBD1 locus on chromosome 16 identified the LRR variants of the 
NOD2 gene as conferring susceptibility to CD [75]. Since this discovery these NOD2 mutations have 
been widely replicated in both adult- and early-onset disease [41,54], with functional studies beginning 
to unravel the role of NOD2 in CD [76,77]. Although initially identified as a cytosolic protein, recent 
studies have shown that NOD2 also resides at the plasma membrane [78]. This membrane localisation 
suggests that NOD2 may function at the sites of bacterial entry to directly engage with pathogens and 
signal an appropriate inflammatory and antimicrobial response [78]. Furthermore, it is proposed that 
NOD2 can recognise danger associated molecular patterns (DAMPs) which are exposed when there is 
disruption of host cell membranes [79]. Some pathogens, such as Salmonella typhimurium and 
enteropathogenic E. coli (EPEC) use type-3-secretion systems (T3SS) to inject effector proteins into 
the cytosol of host cells to mediate adhesion and invasion, and this may act as a DAMP recognised  
by NOD2. 
The first of the seminal papers involving ATG16L1 and NOD2 demonstrated that NOD2 stimulation 
by its ligand muramyl dipeptide (MDP) induced autophagy in human, monocyte-derived dendritic cells 
(DCs) and also influenced bacterial handling and antigen presentation [24]. This was shown to be 
independent of TLR4 signalling and required the NOD2 signalling mediator RIPK-2 in addition to PI3K 
and the autophagy proteins ATG5, ATG7 and ATG16L1. Additionally, they demonstrated that DCs 
isolated from individuals with any of the three known CD-associated NOD2 or T300A ATG16L1 
variants exhibited defective autophagy. Also cells carrying a NOD2 variant failed to localise Salmonella 
enterica and CD-associated adherent-invasive E. coli species to autophagosomes, with this effect 
reversed by artificially inducing autophagy using rapamycin. At the same time a study led by Dana 
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Philpott in Toronto similarly used bone marrow-derived macrophages and macrophages from  
NOD2-deficient mice to demonstrate NOD2-dependent autophagy induction with MDP [80]. 
Interestingly this group highlighted RIPK-2 independent autophagy induction, with colocalisation of 
NOD2 and ATG16L1 at the plasma membrane, with only cells homozygous for the T300A mutation 
effecting autophagy. NOD2 and ATG16L1 were also found to surround invading pathogens at  
the entry foci with mutant NOD2 proteins failing to do so. Homer et al. further showed that  
MDP-activated autophagy and NF-?B signalling, in addition to increased Salmonella killing, was 
dependent on NOD2 and ATG16L1 expression, specifically in intestinal epithelial cells; this response 
was again shown to be altered by known CD-associated NOD2 mutations [81]. The same group has 
most recently show the dual role of RIPK-2 in NOD2-induced autophagy with a positive signal through 
activation of p38 MAPK and reduced autophagy mediated by the phosphatase PP2A [82]. Kuballa et al. 
also showed abnormal capture of internalised Salmonella within autophagosomes in epithelial cells 
carrying the T300A mutation [83]. A summary of the role of ATG16L1 and NOD2 in autophagy and 
the defects demonstrated when CD-associated mutations are present are shown in Figure 3. 
Figure 3. Summary diagram showing the role of ATG16L1 and NOD2 in the autophagy 
pathway and the defects observed when ???????? ???????? ?CD) associated mutations are 
present. The left panel shows the normal autophagy response with NOD2 recruiting 
ATG16L1 to the plasma membrane, normal autophagosome and autophagolysosome 
formation, followed by MHC II antigen presentation and an appropriate adaptive immune 
response. The right panel demonstrates abnormal membrane localisation of ATG16L1 with 
the LRR and T300A mutations resulting in abnormal bacterial killing and defective 
antigen presentation. 
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Further work has now shown that ATG16L1 is intimately involved in autophagosome formation with 
Ravikumar et al. showing that ATG16L1 interacts with the heavy chain of clathrin (a protein that plays 
a major role in the development of coated vesicles [84]) during the formation of ATG16L1-positive  
pre-autophagosomes [85]. This was shown to occur at the plasma membrane, although no obvious 
disruption of the clathrin-ATG16L1 interaction was observed with the T300A mutation. The inflammatory 
cytokine profile of cells possessing the T300A mutation has also been investigated with MDP-stimulation of 
peripheral blood cells harbouring T300A showing increased IL-??????-6 and IL-10 [86,87], in addition 
to a reduction in IFN-? production [88]. Lee et al. went on to show that increased IL-??????????????
was a result of increased p62 levels in ATG16L1-deficient cells [89]. The T300A mutation has also 
recently been shown to produce hyperstable interactions between DCs and T cells at the immune 
synapse, with increased T cell activation, specifically the T-helper 17 cell response [90]. Work 
highlighting the role of ATG16L1 during Helicobacter pylori infection as well as murine norovirus has 
also been presented [91,92]. 
5.2. IRGM 
The immunity-related GTPase (IRG) family of proteins, first described in the 1990s, can be separated 
into IRGA, IRGB, IRGC, IRGD and IRGM subfamilies based on homology across their GTP-binding 
domain, however only two IRG sequences, both transcribed, are present in humans, namely IRGC and 
IRGM [93]. IRGC is not induced by interferons (unlike IRGM) and seems to be very tissue-specific, 
having been shown to be mainly expressed in the testes [93]. To date, five different 3'-splicing isoforms 
have been identified for human IRGM with the protein products of these isoforms predicted to have 
molecular weights of between 19?24 kDa [94]. 
Interferon-gamma (IFN-?) has long been recognised as important cytokine during the cellular 
response to bacterial invasion [95]. One of the first indications that the 47-kDa GTPase family, 
including IRGM, was involved in this response was the observation that genes encoding these proteins 
were upregulated during IFN-? stimulation [96,97]. Culture of murine macrophage and fibroblast lines 
in medium containing high concentrations of IFN-? showed a significant number of cDNA fragments 
belonging to both the 65-kDa and 47-kDa GTPases, including Irgm1 (also known as LRG-47, the 
murine homologue of IRGM). Following this, work by MacMicking et al. demonstrated that Irgm1 null 
mice failed to control Mycobacterium tuberculosis replication, with defective bacterial killing of 
mycobacterium-containing phagosomes in null macrophages [98]. MacMicking et al. also observed 
impaired maturation of Mycobacterium tuberculosis-containing phagosomes suggesting a critical role of 
Irgm1 in vacuolar trafficking; this work was validated in a similar study by Feng et al. [99]. A further 
study investigated this role showing that there was an increase in autophagic vacuoles and the 
maturation of mycobacterial phagosomes in murine macrophages transfected with Irgm1, with Irgm1 
partially co-localising with small LC3-positive organelles [100]. Singh et al. used a number of 
autophagic markers such as monodalsyncadaverine (MDC), Lyso-Tracker (LT) red and Mito-Tracker 
(MT) red to demonstrate early autophagic vacuoles, vacuole acidity and the presence of mitochondrial 
material in vacuoles respectively, induced by over-expressing Irgm1 in murine macrophages [101]. 
However, more interestingly, they also demonstrated that human IRGM participates in autophagy 
induced conventionally (by the use of rapamycin or serum starvation) and by IFN-? in human 
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macrophages, and confirmed an increase in mycobacterial survival using siRNA to IRGM. More recent 
work has also shown that IRGM participates in virus-induced autophagy, with siRNA knockdown of 
IRGM decreasing the number of autophagosomes induced by measles virus, hepatitis C virus and HIV 
proteins [102]. Although many other studies have confirmed the importance of IRGM in cellular 
resistance to a number of pathogens [103,104] some conflicting evidence still exists [105].  
5.3. LRRK2 
Leucine-rich repeat serine/threonine protein kinase 2 (LRRK2; also known as PARK8) is a  
multi-domain protein of 2527 amino acids [106]. This large ubiquitous protein with multiple functional 
domains, namely kinase, ROC GTPase, Cor, leucine-rich repeat, ankyrin and WD40 [107] has been 
linked to CD through the association of a SNP on chromosome 12q12 [108]. LRRK2 is expressed in a 
large number of murine tissues, including lung, heart, kidney and small intestine [109]. In addition, 
recent work has demonstrated that full length LRRK2 is a common constituent of human peripheral 
blood mononuclear cells such as CD14+ monocytes, CD19+ B cells and CD8+ and CD4+ T cells [110].  
To date, little work has focussed on the potential functional role of LRRK2 in CD pathogenesis. 
However, due to mutations in LRRK2 having been consistently associated with Parkinson?s disease 
(PD) (a neurodegenerative disease characterised by progressive disturbances in motor, autonomic and 
psychiatric functions [111]) an increasing number of studies are now beginning to unravel the complex 
functions of this protein. The best characterised mutation in LRRK2 (G2019S?a glycine to serine 
substitution at amino acid 2019) was initially demonstrated in several familial cases of PD [112] and 
subsequently common variations in LRRK2 have been shown to contribute to the risk of sporadic  
PD [113,114]. This, coupled with the previously established importance of autophagy in a number of 
neurodegenerative diseases [115], has focussed current research on the role of LRRK2 during the 
autophagic process.  
LRRK2 has been shown to localise to vesicular granular structures of the late endosomal-lysosomal 
pathways [116?118]. Several membrane microdomains such as the neck of caveolae, microvilli/filopodia 
and intraluminal vesicles of multivesicular bodies (MVBs) were shown to contain LRRK2, as well as 
cytoplasmic puncta corresponding to MVBs and autophagic vacuoles [116]. A recent study 
demonstrated that overexpression of wild-type LRRK2 increased autophagy through activation of a 
calcium-dependent protein kinase kinase-?? ??????-?)/adenosine monophosphate (AMP)-activated 
protein kinase (AMPK) pathway [119]. This effect was through nicotinic-acid adenine dinucleotide 
phosphate (NAADP) receptors causing calcium efflux and partial alkalinisation of lysosomal store pH. 
Increased LC3 punctae were also visualised with overexpression of full-length LRRK2, but not the 
mutant protein, suggesting involvement of the kinase domain. Further work has provided evidence that 
the presence of the G2019S-mutant protein in neuronal cells leads to the accumulation of autophagic 
structures, with an impaired autophagic balance also demonstrated in non-neuronal and yeast  
cells [119]; induced pluripotent stem cells from patients with the G2019S mutation also show an 
accumulation of autophagic vacuoles [120]. Similarly, aged LRRK2-null mice show increased LC3-II 
and p62 in the kidney with a subsequent inflammatory response [121]. 
More pertinent to CD pathogenesis, work by Liu et al. showed that LRRK2-deficient mice had 
significantly poorer clinical outcomes in an experimental (DSS-induced) colitis model compared to their 
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wild-type counterparts, manifested as increased weight loss and diarrhoea [122]. Further work by 
Gardet et al. in human subjects used peripheral blood mononuclear cells and intestinal biopsies from 
IBD patients to further delineate the role of LRRK2 [123]. Stimulation of macrophage-differentiated 
THP-1 cells with IFN-? showed an increase in both LRRK2 mRNA and protein, with PBMCs from 
healthy controls showing a similar response in CD3+ T cells, CD19+ B cells and CD11b+ monocytes. 
LRRK2 mRNA expression was also shown to be increased 6-fold in inflamed CD biopsies  
compared to paired non-inflamed biopsies, with histological specimens showing LRRK2-positivity in 
CD206 macrophages, CD103+ dendritic cells and CD20- B cells. Gardet et al. also showed using  
luciferase-based reporters that LRRK2 can activate NF-?B pathways dependent on the IKK complex. 
Particularly relevant to CD they also demonstrated that LRRK2 co-localised with S. typhimurium in the 
cytosol of RAW macrophages, with LRRK2 siRNA knockdown reducing reactive oxygen species after 
IFN-? stimulation and increased S. typhimurium survival in a gentamicin-protection assay. Extending 
this work, Hakimi et al. showed that LRRK2 is present in a subset of circulating leucocytes with the 
expression of R1441Cmutant LRRK2 in a primary, non-neural cell model revealing an autophagy defect 
manifested as a reduction of LC3-II levels [110]. Stimulation of murine bone-marrow derived 
macrophages by a variety of pattern-recognition receptor ligands (which are likely to be pivotal in CD 
pathogenesis [124]) produced up-regulation of LRRK2 mRNA with respect to LPS, R837 and CpG and 
down-regulation when stimulated with Pam3CSK4.  
5.4. MTMR3 
MTMR3 encodes a protein of the tyrosine phosphatase superfamily [125]. The MTMR proteins are 
involved in the regulation of phosphatidylinositol (PtdIns) and its derivatives, accounting for around 
10% of the total lipid in eukaryotic membranes [126]. This family of proteins (a subgroup of the 
PtdIns(3)P phosphatases) has 15 members, only nine of which (including MTMR3) possess the active 
phosphatase domain that specifically dephosphorylates PtdIns(3)P [127]. PtdIns(3)P is highly enriched 
as a component of the elongating isolation membrane and autophagosome membranes in yeast [128], 
with MTMR3 ubiquitously expressed and shown to hydrolyse PtdIns(3)P to its derivative PtdIns [129]. 
Roles in autophagosome size and constitutive autophagy initiation in epithelial cells [130], coupled with 
hVps34 (a class III PI 3-kinase) being intimately involved in autophagy and the suppression of autophagy by 
the PI 3-kinase inhibitor Wortmannin, makes this group of proteins of particular interest [131,132]. 
PtdIns(3)P has specifically been shown to bind to the autophagy protein ATG18 [133?135] and this 
ATG18-PtdIns(3)P interaction has now been recognised as an essential component for the efficient 
progression of both selective and non-selective autophagy [136]. It is likely that the ATG18-PtdIns(3)P 
complex exerts this role through the interaction of the ATG18-ATG2 complex with ATG9 which is the 
only known integral membrane ATG protein [137]. Further work has now extended the role of 
MTMR3 specifically in autophagy. Work in alveolar basal epithelium (A549 cells) by Taguchi-Atarashi 
et al. showed that overexpression of mutant MTMR3 (MTMR3C413S) produced an increase in GFP-LC3 
and GFP-ATG5 which was not seen with wild-type overexpression [131]. Also, this increase in 
autophagy was dependent on PtdIns(3)P, with siRNA knockdown of MTMR3 producing a similar 
response, suggesting MTMR3 as a negative regulator of autophagy. The 22q12 locus harbouring 
MTMR3 has now also been associated with lung cancer [138], with specific MTMR3 mutations 
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discovered in gastric and colorectal cancer [139], all of which may be important in the context of the 
emerging role of autophagy in cancer biology [140]. 
5.5. PTPN2 
The PTPN2 gene is located on chromosome 18p11 and codes T cell protein tyrosine phosphatase 
(TC-PTP, also known simply as PTPN2), one of over 100 PTP proteins capable of removing phosphate 
moieties from tyrosine residues of protein substrates [141]. First cloned in 1989 [142], this ubiquitous 
protein exists as two splice variants, one localised to the nucleus and the other to the endoplasmic 
reticulum [141]. Much of the functional work surrounding this protein has been through investigation of 
PTPN2 knockout mice that demonstrate a progressive systemic inflammation and abnormal cytokine 
environment [143]. TC-PTP has also been shown to be involved in haematopoiesis and autoimmune 
disease [141].  
Much of the work specifically relating to the role of PTPN2 and CD has been performed by  
Scharl et al. The first of these papers studied the role of PTPN2 in intestinal barrier function. They 
demonstrated that PTPN2 was over-expressed in biopsies from CD patients, and that stimulation of an 
intestinal epithelial cell (IEC) line with IFN-? increased PTPN2 levels [144]. Also, PTPN2 knockdown 
increased STAT1 and STAT3 phosphorylation after IFN-? stimulation and increased epithelial permeability 
as determined by FITC-Dextran flux across IEC monolayers. Similar increases in IL-6 and macrophage 
chemoattractant protein 1 (MCP-1) were seen with PTPN2 knockdown in a monocyte cell line in a 
subsequent study [145]. Other work showed comparable results when IECs were stimulated with  
TNF-? [146]. Very recent research has now shown a role for PTPN2 in autophagy with siRNA 
knockdown in IECs reducing autophagosome formation as well as autophagy induction as determined 
by persisting Listeria infection; this was replicated in colonic lamina propria fibroblasts from patients 
with CD carrying the PTPN2 variant [147]. Additionally a novel variant in PTPN2 (rs1893217) was 
also shown to impair autophagosome formation, as well as elevating IFN-? levels in response to  
MDP [148]. 
5.6. NCF4 and ULK1 
One of the first GWAS to identify the association of autophagy genes with CD susceptibility 
postulated NCF4 as a candidate gene [35]. Although this finding was replicated soon afterwards [63], 
several studies have also proved negative [64,149]. NCF4 (also known as p40phox) is a member of the 
cytoplasmic SH3-domain proteins involved in the activation of gp91phox during phagocytosis [150]. 
Along with other phox proteins (e.g., p67phox) NCF4 is involved in the generation of reactive oxygen 
species (ROS) by the reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex, 
which is critical in the antimicrobial functions of phagocytic cells [151]. In addition to NCF4-deficient 
mice showing defective killing of S. aureus [151], ROS have also been shown to be important during 
autophagy induction [152]. A limited number of studies have demonstrated an association with an  
ileal [63,153] or perianal [154] phenotype with one functional study showing a reduction in reduced 
ROS in GM-CSF-primed granulocytes from CD patients harbouring the NCF4 mutation [155].  
To date only two studies have evaluated the role of the well-characterised autophagy protein ULK1 
in CD pathogenesis. The first of these demonstrated that the SNP rs12303764 near ULK1 was 
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significantly associated with CD in a case-control study, replicated in a transmission disequilibrium test 
in 335 case-parent trios [61]. This association with ULK1 variants was then recently replicated in an 
independent case-control study in New Zealand [62]. Although the association with rs12303764 was 
not present in their population, several other SNPs in the region of ULK1 showed positive association, 
however the replication for these SNPs in larger GWAS meta-analysis data was variable. The ULK1 
gene, consisting of 28 exons, with a transcript length of 5211 basepairs and a translation length of 1050 
residues, is localised on chromosome 12q24. The two known mammalian orthologs of yeast Atg1, 
ULK1 and ULK2, form a stable complex with ATG13, FIP200, ATG101 and mTORC1. Although this 
complex is intimately involved in autophagy induction, in view of its currently weak association with 
CD a detailed discussion of the role of ULK1 in autophagy is outwith the scope of this article; however 
several excellent reviews of its biological function are available [156,157].  
It has yet to be seen what direct role CD-association variants in NCF4 and ULK1 will play, if any, in 
CD pathogenesis. However future research will undoubtedly endeavour to illicit any further association 
given the vital role of ULK1 in the mTORC1 complex and the intriguing importance of ROS in bacterial 
handling. A summary of the postulated autophagy-related pathways influenced by the lesser-studied CD 
susceptibility proteins are outlined in Figure 4. 
Figure 4. Postulated autophagy-related pathways influenced by CD susceptibility proteins 
currently under more detailed investigation.  
 
6. Adherent Invasive E. coli 
E. coli is normally a harmless commensal micro-organism that can become a highly-adapted 
pathogen through the acquisition of specific virulence factors. To date eight pathovars have been 
extensively studied and implicated in a wide range of diseases, of which enteropathogenic E. coli 
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(EPEC), enterohaemorrhagic E. coli (EHEC), enterotoxinogenic E. coli (ETEC) and diffusely adherent 
E. coli (DAEC) cause gastroenteritis in humans [158]. In addition there are several recently described 
E. coli pathovars, of which AIEC are the most relevant to CD. The association of AIEC with CD was 
first reported by Darfeuille-Michaud and colleagues in the late nineties [159,160], and since then AIEC 
have been isolated from independent studies involving adult and paediatric CD patients [7,8,161]. The 
high prevalence of AIEC strains observed in the ileal mucosa of CD patients has been attributed to their 
ability to adhere to the glycosylated carcinoembryonic antigen-related cell adhesion molecule 6 
(CEACAM6), which is overexpressed on the surface of epithelial cells in patients with CD [162]. In 
addition the ER-stress response chaperone Gp96 is highly expressed in epithelial cells of patients with 
CD and has been demonstrated to act as a host cell receptor for AIEC [163]. Recently, complete 
genome sequencing of the reference strain of CD-associated AIEC LF82 has shown that this strain 
contains several virulence factors including the lpf operon, which encodes long polar fimbriae (LPF) [164]. 
AIEC have also been shown to interact with ???????? patches, specialised cells of the intestinal 
epithelium via LPF, and the prevalence of AIEC strains containing the lpf operon was shown to be 
markedly higher in CD-patients compared to controls [165].  
Following adhesion AIEC can invade the intestinal epithelium, breaching the epithelial barrier and are 
subsequently found in the lamina propria of patients with ileal CD. A recent study investigated the role 
of autophagy in the replication and survival of E. coli in epithelial cells [166]. Specifically, the authors 
investigated whether cells deficient in the CD-associated autophagy proteins IRGM and ATG16L1 
affected intracellular replication and survival of AIEC strains. This study demonstrated that the AIEC 
strain LF82 have enhanced replication and survival in both IRGM and ATG16L1 deficient cells. 
Remarkably, autophagy deficiency did not interfere with the replication and survival ability of other E. 
coli strains tested, including non-pathogenic, environmental, commensal, or pathogenic strains involved 
in gastroenteritis, suggesting a specific role for autophagy in restraining AIEC. AIEC can translocate 
the epithelium into the lamina propria where they can replicate and survive within macrophages. In a 
subsequent study the same group investigated whether defects in autophagy affected the replication and 
survival of AIEC in macrophages [167]. AIEC were shown to recruit the autophagy machinery to sites 
of entry into host cells and autophagy limited intramacrophagic replication. Impaired IRGM or 
ATG16L1 expression resulted in increased AIEC in macrophages and significantly this was 
accompanied by increased secretion of the pro-inflammatory cytokines IL-6 and TNF-?. Further studies 
demonstrate that a family of micro-RNA (miRNAs) miR-196 that are expressed in the intestinal 
epithelium of individuals with CD down regulate the expression of IRGM in those with the protective 
variant (c.313C) [168]. The resulting impairment of the autophagy response results in increased 
intracellular replication and survival of AIEC. Taken altogether these studies suggest that stimulation of 
autophagy, perhaps using small molecule inhibitors of mTORC1, would be a therapeutic strategy to 
restrain AIEC replication and dampen the exacerbated inflammatory response that leads to chronic 
inflammation and granuloma formation observed in patients with CD.  
7. Autophagy Pathway-Phenotype Correlations in Crohn?s Disease  
A number of studies have now endeavoured to correlate CD phenotypes with autophagy gene risk 
variants in an attempt to translate knowledge of the autophagy pathway to clinical application. The most 
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replicated finding in this respect is the positive association of ATG16L1 and IRGM variants with ileal 
disease phenotype. Along with Prescott et al. who initially reported this finding for ATG16L1 in a 
cohort from the United Kingdom [34], groups in Australia [169] and Portugal [57] have recognised this 
relationship, with the Portuguese group also showing this association for IRGM. Similarly carriage of 
the ATG16L1 risk variant has been shown to correlate with a reduction in extra-intestinal 
manifestations; however the small patient numbers in this report may have been a confounding 
factor [170]. Another reported positive association was with IRGM variants and the need for 
ileocolectomy (a surgical procedure to remove the affected distal small bowel and proximal large 
bowel), however the number of patients in the study again make this difficult to interpret [171]. Several 
recent studies have attempted to define the association of autophagy gene risk variants with the 
presence of granulomas on intestinal biopsy samples, with conflicting results. (A granuloma is an 
inflammatory lesion containing epithelioid cells, macrophages, and lymphocytes, and is considered one 
of the pathological hallmarks of CD, however detection at endoscopy is variable [172]). Wolfkamp et 
al. in a cohort of approximately 200 patients demonstrated no association of granulomas with CD-risk 
variants in ATG16L1 or IRGM [173]. SNPs in NCF4 and ATG4A have also shown negative correlation 
with the presence of granulomas in an Israeli cohort [174]. A larger study from Belgium, which 
included 464 patients, did find both a positive and negative association of variations in four  
autophagy-related genes (ATG2A, ATG4A, ATG4D and FNBP1L); to date these genes have not been 
shown to confer a susceptibility risk to, or altered protein expression in, CD [175]. 
The role of the microbiome in the pathogenesis of CD has become more prominent in recent  
years [5], a small number of studies have aimed to determine the relationship between autophagy  
risk-variants and microbial components. Murdoch et al. looked at the presence of four antimicrobial 
antibodies stratified by CD-associated variants [176]. They showed that in a cohort over 600 CD 
patients, that increased seropositivity for anti-Saccharomyces cerevisiae antibody (ASCA) was associated 
with carriage of the ATG16L1 variant and that the IRGM CD-risk variant was associated with 
increased anti-flagellin seropositivity. Frank et al. looked at DNA extracted from intestinal specimens 
from 35 CD patients to determine the microbial composition and its relationship with genotype [177]. 
16S rRNA sequence analysis revealed that patients with the NOD2 or ATG16L1 variants had 
significantly altered microbiota, although the authors did acknowledge that the study was underpowered 
to determine any genera-specific effects.  
8. Conclusions 
It can be seen that following the emergence of autophagy as a pathogenic mechanism in CD that 
some progress has been made to unravel the functional aspects of these complex pathways. To date 
much of the research surrounding this topic has been focussed on genetic susceptibility and despite the 
field of autophagy progressing at a rapid pace, much is still unknown regarding the precise molecular 
abnormalities that may underlie the disease process. It is likely that further knowledge of the autophagy 
proteins involved specifically in CD and a deeper insight into the role of xenophagy (especially in the 
context of AIEC and the ileal disease phenotype) will be required before effective intervention can be 
implemented to alter the disease course. Functional work is now required to determine the potential 
therapeutic modulation of both the autophagy pathway itself, in addition to targeting specific bacterial 
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subgroups such as AIEC, although these therapies will most likely only be beneficial in a small number 
of patients. 
Conflict of Interest 
The authors declare no conflict of interest.  
References  
1. Bernstein, C.N.; Loftus, E.V., Jr.; Ng, S.C.; Lakatos, P.L.; Moum, B. Hospitalisations and 
surgery in Crohn?s disease. Gut 2012, 61, 622?629. 
2. Van Limbergen, J.; Russell, R.K.; Drummond, H.E.; Aldhous, M.C.; Round, N.K.; Nimmo, E.R.; 
Smith, L.; Gillett, P.M.; McGrogan, P.; Weaver, L.T.; et al. Definition of phenotypic characteristics  
of childhood-onset inflammatory bowel disease. Gastroenterology 2008, 135, 1114?1122. 
3. Henderson, P.; van Limbergen, J.; Wilson, D.C.; Satsangi, J.; Russell, R.K. Genetics of childhood-onset 
inflammatory bowel disease. Inflamm. Bowel Dis. 2011, 17, 346?361. 
4. Armitage, E.L.; Aldhous, M.C.; Anderson, N.; Drummond, H.E.; Riemersma, R.A.; Ghosh, S.; 
Satsangi, J.; Armitage, E.L.; Aldhous, M.C.; Anderson, N.; et al. Incidence of juvenile-onset 
Crohn?s disease in Scotland: Association with northern latitude and affluence. Gastroenterology 
2004, 127, 1051?1057. 
5. Mukhopadhya, I.; Hansen, R.; El-Omar, E.M.; Hold, G.L. IBD-what role do Proteobacteria play? 
Nat. Rev. Gastroenterol. Hepatol. 2012, 9, 219?230. 
6. Franke, A.; McGovern, D.P.; Barrett, J.C.; Wang, K.; Radford-Smith, G.L.; Ahmad, T.; Lees, C.W.; 
Balschun, T.; Lee, J.; Roberts, R.; et al. Genome-wide meta-analysis increases to 71 the number 
of confirmed Crohn?s disease susceptibility loci. Nat. Genet. 2010, 42, 1118?1125. 
7. Raso, T.; Crivellaro, S.; Chirillo, M.G.; Pais, P.; Gaia, E.; Savoia, D. Analysis of E. coli isolated 
from patients affected by Crohn?s disease. Curr. Microbiol. 2011, 63, 131?137. 
8. Negroni, A.; Costanzo, M.; Vitali, R.; Superti, F.; Bertuccini, L.; Tinari, A.; Minelli, F.; Di Nardo, G.; 
Nuti, F.; Pierdomenico, M.; et al. Characterization of adherent-invasive E. coli isolated from 
pediatric patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2012, 18, 913?924. 
9. Clague, M.J.; Urbe, S. Ubiquitin: Same molecule, different degradation pathways. Cell 2010, 143, 
682?685. 
10. Wirawan, E.; Vanden Berghe, T.; Lippens, S.; Agostinis, P.; Vandenabeele, P. Autophagy: For 
better or for worse. Cell Res. 2012, 22, 43?61. 
11. Rabinowitz, J.D.; White, E. Autophagy and metabolism. Science 2010, 330, 1344?1348. 
12. Saftig, P.; Klumperman, J. Lysosome biogenesis and lysosomal membrane proteins: Trafficking 
meets function. Nat. Rev. Mol. Cell Biol. 2009, 10, 623?635. 
13. Kaushik, S.; Cuervo, A.M. Chaperone-mediated autophagy. Methods Mol. Biol. 2008, 445,  
227?244. 
14. Kettern, N.; Dreiseidler, M.; Tawo, R.; Hohfeld, J. Chaperone-assisted degradation: Multiple 
paths to destruction. Biol. Chem. 2010, 391, 481?489. 
15. Li, W.W.; Li, J.; Bao, J.K. Microautophagy: Lesser-known self-eating. Cell Mol. Life Sci. 2012, 
69, 1125?1136. 
Cells 2012, 1 508 
 
16. De Duve, C.; Wattiaux, R. Functions of lysosomes. Annu. Rev. Physiol. 1966, 28, 435?492. 
17. Sridhar, S.; Botbol, Y.; Macian, F.; Cuervo, A.M. Autophagy and disease: Always two sides to a 
problem. J. Pathol. 2012, 226, 255?273. 
18. Cuervo, A.M. The plasma membrane brings autophagosomes to life. Nat. Cell Biol. 2010, 12, 
735?737. 
19. Levine, B.; Kroemer, G. Autophagy in the pathogenesis of disease. Cell 2008, 132, 27?42. 
20. Van Limbergen, J.; Stevens, C.; Nimmo, E.R.; Wilson, D.C.; Satsangi, J. Autophagy: From basic 
science to clinical application. Mucosal Immunol. 2009, 2, 315?330. 
21. Weidberg, H.; Shvets, E.; Elazar, Z. Biogenesis and cargo selectivity of autophagosomes.  
Annu. Rev. Biochem. 2011, 80, 125?156. 
22. Deretic, V.; Levine, B. Autophagy, immunity, and microbial adaptations. Cell Host Microbe 2009, 
5, 527?549. 
23. McGreal, E.P. Structural basis of pattern recognition by innate immune molecules. Adv. Exp. 
Med. Biol. 2009, 653, 139?161. 
24. Cooney, R.; Baker, J.; Brain, O.; Danis, B.; Pichulik, T.; Allan, P.; Ferguson, D.J.; Campbell, B.J.; 
Jewell, D.; Simmons, A. NOD2 stimulation induces autophagy in dendritic cells influencing 
bacterial handling and antigen presentation. Nat. Med. 2010, 16, 90?97. 
25. Delgado, M.A.; Deretic, V. Toll-like receptors in control of immunological autophagy. Cell Death 
Differ. 2009, 16, 976?983. 
26. Shin, D.M.; Yuk, J.M.; Lee, H.M.; Lee, S.H.; Son, J.W.; Harding, C.V.; Kim, J.M.; Modlin, R.L.; 
Jo, E.K. Mycobacterial lipoprotein activates autophagy via TLR2/1/CD14 and a functional 
vitamin D receptor signalling. Cell Microbiol. 2010, 12, 1648?1665. 
27. Munz, C. Antigen processing for MHC class II presentation via autophagy. Front. Immunol. 
2012, 3, 9. 
28. Lamark, T.; Kirkin, V.; Dikic, I.; Johansen, T. NBR1 and p62 as cargo receptors for selective 
autophagy of ubiquitinated targets. Cell Cycle 2009, 8, 1986?1990. 
29. Fujita, N.; Yoshimori, T. Ubiquitination-mediated autophagy against invading bacteria.  
Curr. Opin. Cell Biol. 2011, 23, 492?497. 
30. Cemma, M.; Kim, P.K.; Brumell, J.H. The ubiquitin-binding adaptor proteins p62/SQSTM1 and 
NDP52 are recruited independently to bacteria-associated microdomains to target Salmonella to 
the autophagy pathway. Autophagy 2011, 7, 341?345. 
31. Wild, P.; Farhan, H.; McEwan, D.G.; Wagner, S.; Rogov, V.V.; Brady, N.R.; Richter, B.; Korac, J.; 
Waidmann, O.; Choudhary, C.; et al. Phosphorylation of the autophagy receptor optineurin 
restricts Salmonella growth. Science 2011, 333, 228?233. 
32. Hampe, J.; Franke, A.; Rosenstiel, P.; Till, A.; Teuber, M.; Huse, K.; Albrecht, M.; Mayr, G.;  
de La Vega, F.M.; Briggs, J.; et al. A genome-wide association scan of nonsynonymous SNPs 
identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 2007, 39, 207?211. 
33. Van Limbergen, J.; Kabakchiev, B.; Stempak, J.; Schumm, P.; Xu, W.; Henderson, P.; Griffiths, A.; 
Girardin, S.E.; Philpott, D.; Silverberg, M. Detailed analysis of ATG16L1 demonstrates  
gene-wide extent of association with ????????disease susceptibility. Gut 2012, 61, A4. 
Cells 2012, 1 509 
 
34. Prescott, N.J.; Fisher, S.A.; Franke, A.; Hampe, J.; Onnie, C.M.; Soars, D.; Bagnall, R.;  
Mirza, M.M.; Sanderson, J.; Forbes, A.; et al. A nonsynonymous SNP in ATG16L1 predisposes 
to ileal Crohn?s disease and is independent of CARD15 and IBD5. Gastroenterology 2007, 132, 
1665?1671. 
35. Rioux, J.D.; Xavier, R.J.; Taylor, K.D.; Silverberg, M.S.; Goyette, P.; Huett, A.; Green, T.; 
Kuballa, P.; Barmada, M.M.; Datta, L.W.; et al. Genome-wide association study identifies new 
susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis.  
Nat. Genet. 2007, 39, 596?604. 
36. Cummings, J.R.; Cooney, R.; Pathan, S.; Anderson, C.A.; Barrett, J.C.; Beckly, J.; Geremia, A.; 
Hancock, L.; Guo, C.; Ahmad, T.; et al. Confirmation of the role of ATG16L1 as a Crohn?s 
disease susceptibility gene. Inflamm. Bowel Dis. 2007, 13, 941?946. 
37. Parkes, M.; Barrett, J.C.; Prescott, N.J.; Tremelling, M.; Anderson, C.A.; Fisher, S.A.; Roberts, R.G.; 
Nimmo, E.R.; Cummings, F.R.; Soars, D.; et al. Sequence variants in the autophagy gene IRGM 
and multiple other replicating loci contribute to Crohn?s disease susceptibility. Nat. Genet. 2007, 
39, 830?832. 
38. Weersma, R.K.; Zhernakova, A.; Nolte, I.M.; Lefebvre, C.; Rioux, J.D.; Mulder, F.;  
van Dullemen, H.M.; Kleibeuker, J.H.; Wijmenga, C.; Dijkstra, G. ATG16L1 and IL23R are 
associated with inflammatory bowel diseases but not with celiac disease in The Netherlands.  
Am. J. Gastroenterol. 2008, 103, 621?627. 
39. Buning, C.; Durmus, T.; Molnar, T.; de Jong, D.J.; Drenth, J.P.; Fiedler, T.; Gentz, E.; Todorov, T.; 
Haas, V.; Buhner, S.; et al. A study in three European IBD cohorts confirms that the ATG16L1 
c.898A > G (p.Thr300Ala) variant is a susceptibility factor for Crohn?s disease. J. Crohn?s Colitis 
2007, 1, 70?76. 
40. Cotterill, L.; Payne, D.; Levinson, S.; McLaughlin, J.; Wesley, E.; Feeney, M.; Durbin, H.; Lal, S.; 
Makin, A.; Campbell, S.; et al. Replication and meta-analysis of 13,000 cases defines the risk for 
interleukin-23 receptor and autophagy-related 16-like 1 variants in Crohn?s disease. Can. J. 
Gastroenterol. 2010, 24, 297?302. 
41. Barrett, J.C.; Hansoul, S.; Nicolae, D.L.; Cho, J.H.; Duerr, R.H.; Rioux, J.D.; Brant, S.R.; 
Silverberg, M.S.; Taylor, K.D.; Barmada, M.M.; et al. Genome-wide association defines more 
than 30 distinct susceptibility loci for Crohn?s disease. Nat. Genet. 2008, 40, 955?962. 
42. Zhang, H.F.; Qiu, L.X.; Chen, Y.; Zhu, W.L.; Mao, C.; Zhu, L.G.; Zheng, M.H.; Wang, Y.;  
Lei, L.; Shi, J. ATG16L1 T300A polymorphism and Crohn?s disease susceptibility: Evidence from 
13,022 cases and 17,532 controls. Hum. Genet. 2009, 125, 627?631. 
43. Yamazaki, K.; Onouchi, Y.; Takazoe, M.; Kubo, M.; Nakamura, Y.; Hata, A. Association analysis 
of genetic variants in IL23R, ATG16L1 and 5p13.1 loci with Crohn?s disease in Japanese patients. 
J. Hum. Genet. 2007, 52, 575?583. 
44. Yang, S.K.; Park, M.; Lim, J.; Park, S.H.; Ye, B.D.; Lee, I.; Song, K. Contribution of IL23R but 
not ATG16L1 to ???????? disease susceptibility in Koreans. Inflamm. Bowel Dis. 2009, 15,  
1385?1390. 
Cells 2012, 1 510 
 
45. Zhi, J.; Zhi, F.C.; Chen, Z.Y.; Yao, G.P.; Guan, J.; Lin, Y.; Zhang, Y.C. Correlation of the 
autophagosome gene ATG16L1 polymorphism and inflammatory bowel disease. Nan Fang Yi Ke 
Da Xue Xue Bao 2008, 28, 649?651. 
46. Lacher, M.; Schroepf, S.; Ballauff, A.; Lohse, P.; von Schweinitz, D.; Kappler, R.; Koletzko, S. 
Autophagy 16-like 1 rs2241880 G allele is associated with Crohn?s disease in German children. 
Acta Paediatr. 2009, 98, 1835?1840. 
47. Baldassano, R.N.; Bradfield, J.P.; Monos, D.S.; Kim, C.E.; Glessner, J.T.; Casalunovo, T.; 
Frackelton, E.C.; Otieno, F.G.; Kanterakis, S.; Shaner, J.L.; et al. Association of the T300A  
non-synonymous variant of the ATG16L1 gene with susceptibility to paediatric Crohn?s disease. 
Gut 2007, 56, 1171?1173. 
48. Van Limbergen, J.; Russell, R.K.; Nimmo, E.R.; Drummond, H.E.; Smith, L.; Anderson, N.H.; 
Davies, G.; Gillett, P.M.; McGrogan, P.; Weaver, L.T.; et al. Autophagy gene ATG16L1 
influences susceptibility and disease location but not childhood-onset in Crohn?s disease in 
Northern Europe. Inflamm. Bowel Dis. 2008, 14, 338?346. 
49. Gazouli, M.; Pachoula, I.; Panayotou, I.; Mantzaris, G.; Chrousos, G.; Anagnou, N.P.;  
Roma-Giannikou, E. NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and  
childhood-onset of Crohn?s disease. World J. Gastroenterol. 2010, 16, 1753?1758. 
50. Wellcome Trust Case Control Consortium (WTCCC). Genome-wide association study of 14,000 
cases of seven common diseases and 3,000 shared controls. Nature 2007, 447, 661?678. 
51. Palomino-Morales, R.J.; Oliver, J.; Gomez-Garcia, M.; Lopez-Nevot, M.A.; Rodrigo, L.;  
Nieto, A.; Alizadeh, B.Z.; Martin, J. Association of ATG16L1 and IRGM genes polymorphisms 
with inflammatory bowel disease: A meta-analysis approach. Genes Immun. 2009, 10, 356?364. 
52. Moon, C.M.; Shin, D.J.; Kim, S.W.; Son, N.H.; Park, A.; Park, B.; Jung, E.S.; Kim, E.S.;  
Hong, S.P.; Kim, T.I.; et al. Associations between genetic variants in the IRGM gene and inflammatory 
bowel diseases in the Korean population. Inflamm. Bowel Dis. 2012, doi:10.1002/ibd.22972. 
53. Van Limbergen, J.; Russell, R.K.; Nimmo, E.R.; Drummond, H.E.; Davies, G.; Wilson, D.C.; 
Satsangi, J. Germline variants of IRGM in childhood-onset ????????disease. Gut 2009, 58, 610?611. 
54. Imielinski, M.; Baldassano, R.N.; Griffiths, A.; Russell, R.K.; Annese, V.; Dubinsky, M.; 
Kugathasan, S.; Bradfield, J.P.; Walters, T.D.; Sleiman, P.; et al. Common variants at five new 
loci associated with early-onset inflammatory bowel disease. Nat. Genet. 2009, 41, 1335?1340. 
55. Phillips, A.M.; Nimmo, E.R.; van Limbergen, J.; Drummond, H.E.; Smith, L.; Satsangi, J. 
Detailed haplotype-tagging study of germline variation of MUC19 in inflammatory bowel disease. 
Inflamm. Bowel Dis. 2010, 16, 557?558. 
56. Torkvist, L.; Halfvarson, J.; Ong, R.T.; Lordal, M.; Sjoqvist, U.; Bresso, F.; Bjork, J.; Befrits, R.; 
Lofberg, R.; Blom, J.; et al. Analysis of 39 Crohn?s disease risk loci in Swedish inflammatory 
bowel disease patients. Inflamm. Bowel Dis. 2010, 16, 907?909. 
57. Duraes, C.; Machado, J.C.; Portela, F.; Rodrigues, S.; Lago, P.; Cravo, M.; Ministro, P.; 
Marques, M.; Cremers, I.; Freitas, J.; et al. Phenotype-genotype profiles in Crohn?s disease 
predicted by genetic markers in autophagy-related genes (GOIA study II). Inflamm. Bowel Dis. 
2012, doi:10.1002/ibd.23007. 
Cells 2012, 1 511 
 
58. Weersma, R.K.; Stokkers, P.C.; Cleynen, I.; Wolfkamp, S.C.; Henckaerts, L.; Schreiber, S.; 
Dijkstra, G.; Franke, A.; Nolte, I.M.; Rutgeerts, P.; et al. Confirmation of multiple Crohn?s disease 
susceptibility loci in a large Dutch-Belgian cohort. Am. J. Gastroenterol. 2009, 104, 630?638. 
59. Morgan, A.R.; Han, D.Y.; Huebner, C.; Lam, W.J.; Fraser, A.G.; Ferguson, L.R. PTPN2 but not 
PTPN22 is associated with Crohn?s disease in a New Zealand population. Tissue Antigens 2010, 
76, 119?125. 
60. Amre, D.K.; Mack, D.R.; Morgan, K.; Israel, D.; Deslandres, C.; Seidman, E.G.; Lambrette, P.; 
Costea, I.; Krupoves, A.; Fegury, H.; et al. Susceptibility loci reported in genome-wide 
association studies are associated with Crohn?s disease in Canadian children. Aliment. Pharmacol. 
Ther. 2010, 31, 1186?1191. 
61. Henckaerts, L.; Cleynen, I.; Brinar, M.; John, J.M.; van Steen, K.; Rutgeerts, P.; Vermeire, S. 
Genetic variation in the autophagy gene ULK1 and risk of Crohn?s disease. Inflamm. Bowel Dis. 
2011, 17, 1392?1397. 
62. Morgan, A.R.; Lam, W.J.; Han, D.Y.; Fraser, A.G.; Ferguson, L.R. Association analysis of  
ULK1 with Crohn?s disease in a New Zealand population. Gastroenterol. Res. Pract. 2012,  
doi:10.1155/2012/715309. 
63. Roberts, R.L.; Hollis-Moffatt, J.E.; Gearry, R.B.; Kennedy, M.A.; Barclay, M.L.; Merriman, T.R. 
Confirmation of association of IRGM and NCF4 with ileal Crohn?s disease in a population-based 
cohort. Genes Immun. 2008, 9, 561?565. 
64. Glas, J.; Seiderer, J.; Pasciuto, G.; Tillack, C.; Diegelmann, J.; Pfennig, S.; Konrad, A.; Schmechel, S.; 
Wetzke, M.; Torok, H.P.; et al. rs224136 on chromosome 10q21.1 and variants in PHOX2B, 
NCF4, and FAM92B are not major genetic risk factors for susceptibility to Crohn?s disease in the 
German population. Am. J. Gastroenterol. 2009, 104, 665?672. 
65. Mizushima, N.; Yoshimori, T.; Ohsumi, Y. The role of Atg proteins in autophagosome formation. 
Annu. Rev. Cell Dev. Biol. 2011, 27, 107?132. 
66. Fujita, N.; Itoh, T.; Omori, H.; Fukuda, M.; Noda, T.; Yoshimori, T. The Atg16L complex 
specifies the site of LC3 lipidation for membrane biogenesis in autophagy. Mol. Biol. Cell 2008, 
19, 2092?2100. 
67. Mizushima, N.; Yamamoto, A.; Hatano, M.; Kobayashi, Y.; Kabeya, Y.; Suzuki, K.; Tokuhisa, T.; 
Ohsumi, Y.; Yoshimori, T. Dissection of autophagosome formation using Apg5-deficient mouse 
embryonic stem cells. J. Cell Biol. 2001, 152, 657?668. 
68. Itoh, T.; Fujita, N.; Kanno, E.; Yamamoto, A.; Yoshimori, T.; Fukuda, M. Golgi-resident small 
GTPase Rab33B interacts with Atg16L and modulates autophagosome formation. Mol. Biol. Cell 
2008, 19, 2916?2925. 
69. Saitoh, T.; Fujita, N.; Jang, M.H.; Uematsu, S.; Yang, B.G.; Satoh, T.; Omori, H.; Noda, T.; 
Yamamoto, N.; Komatsu, M.; et al. Loss of the autophagy protein Atg16L1 enhances  
endotoxin-induced IL-1beta production. Nature 2008, 456, 264?268. 
70. Cadwell, K.; Liu, J.Y.; Brown, S.L.; Miyoshi, H.; Loh, J.; Lennerz, J.K.; Kishi, C.; Kc, W.; 
Carrero, J.A.; Hunt, S.; et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse 
and human intestinal Paneth cells. Nature 2008, 456, 259?263. 
Cells 2012, 1 512 
 
71. Mizushima, N.; Kuma, A.; Kobayashi, Y.; Yamamoto, A.; Matsubae, M.; Takao, T.; Natsume, T.; 
Ohsumi, Y.; Yoshimori, T. Mouse Apg16L, a novel WD-repeat protein, targets to the autophagic 
isolation membrane with the Apg12-Apg5 conjugate. J. Cell Sci. 2003, 116, 1679?1688. 
72. Kuma, A.; Hatano, M.; Matsui, M.; Yamamoto, A.; Nakaya, H.; Yoshimori, T.; Ohsumi, Y.; 
Tokuhisa, T.; Mizushima, N. The role of autophagy during the early neonatal starvation period. 
Nature 2004, 432, 1032?1036. 
73. Shi, J. Defensins and Paneth cells in inflammatory bowel disease. Inflamm. Bowel Dis. 2007, 13, 
1284?1292. 
74. Rosenstiel, P.; Schreiber, S. NOD-like receptors?Pivotal guardians of the immunological 
integrity of barrier organs. Adv. Exp. Med. Biol. 2009, 653, 35?47. 
75. Hugot, J.P.; Chamaillard, M.; Zouali, H.; Lesage, S.; Cezard, J.P.; Belaiche, J.; Almer, S.;  
Tysk, C.; O?Morain, C.A.; Gassull, M.; et al. Association of NOD2 leucine-rich repeat variants 
with susceptibility to Crohn?s disease. Nature 2001, 411, 599?603. 
76. Hewitt, R.E.; Pele, L.C.; Tremelling, M.; Metz, A.; Parkes, M.; Powell, J.J. Immuno-inhibitory 
PD-L1 can be induced by a peptidoglycan/NOD2 mediated pathway in primary monocytic cells 
and is deficient in Crohn?s patients with homozygous NOD2 mutations. Clin. Immunol. 2012, 
143, 162?169. 
77. Stevens, C.; Henderson, P.; Soares, D.; Dogan, B.; Simpson, K.; Barrett, J.C.; International 
Inflammatory Bowel Disease Genetics Consortium (IIBDGC); Wilson, D.C.; Satsangi, J. The 
intermediate filament protein vimentin is a regulator of NOD2 activity. Gut 2012, doi:10.1136/ 
gutjnl-2011-301775. 
78. Philpott, D.J.; Girardin, S.E. Nod-like receptors: Sentinels at host membranes. Curr. Opin. 
Immunol. 2010, 22, 428?434. 
79. Kersse, K.; Bertrand, M.J.; Lamkanfi, M.; Vandenabeele, P. NOD-like receptors and the innate 
immune system: Coping with danger, damage and death. Cytokine Growth Factor Rev. 2011, 22, 
257?276. 
80. Travassos, L.H.; Carneiro, L.A.; Ramjeet, M.; Hussey, S.; Kim, Y.G.; Magalhaes, J.G.; Yuan, L.; 
Soares, F.; Chea, E.; Le Bourhis, L.; et al. Nod1 and Nod2 direct autophagy by recruiting 
ATG16L1 to the plasma membrane at the site of bacterial entry. Nat. Immunol. 2010, 11, 55?62. 
81. Homer, C.R.; Richmond, A.L.; Rebert, N.A.; Achkar, J.P.; McDonald, C. ATG16L1 and NOD2 
interact in an autophagy-dependent, anti-bacterial pathway implicated in Crohn?s disease 
pathogenesis. Gastroenterology 2010, 139, 1630?1641. 
82. Homer, C.R.; Kabi, A.; Marina-Garc, I.A.N.; Sreekumar, A.; Nesvizhskii, A.I.; Nickerson, K.P.; 
Chinnaiyan, A.M.; Nunez, G.; McDonald, C. A dual role for receptor interacting protein kinase 2 
(RIP2) kinase activity in nucleotide-binding oligomerization domain 2 (NOD2)-dependent autophagy. 
J. Biol. Chem. 2012, doi:10.1074/jbc.M111.326835. 
83. Kuballa, P.; Huett, A.; Rioux, J.D.; Daly, M.J.; Xavier, R.J. Impaired autophagy of an intracellular 
pathogen induced by a Crohn?s disease associated ATG16L1 variant. PLoS One 2008, 3, e3391. 
84. McPherson, P.S. Proteomic analysis of clathrin-coated vesicles. Proteomics 2010, 10, 4025?4039. 
85. Ravikumar, B.; Moreau, K.; Jahreiss, L.; Puri, C.; Rubinsztein, D.C. Plasma membrane contributes 
to the formation of pre-autophagosomal structures. Nat. Cell Biol. 2010, 12, 747?757. 
Cells 2012, 1 513 
 
86. Plantinga, T.S.; Crisan, T.O.; Oosting, M.; van de Veerdonk, F.L.; de Jong, D.J.; Philpott, D.J.; 
van der Meer, J.W.; Girardin, S.E.; Joosten, L.A.; Netea, M.G. Crohn?s disease-associated 
ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon 
activation of NOD2. Gut 2011, 60, 1229?1235. 
87. Glubb, D.M.; Gearry, R.B.; Barclay, M.L.; Roberts, R.L.; Pearson, J.; Keenan, J.I.; McKenzie, J.; 
Bentley, R.W. NOD2 and ATG16L1 polymorphisms affect monocyte responses in Crohn?s 
disease. World J. Gastroenterol. 2011, 17, 2829?2837. 
88. Kleinnijenhuis, J.; Oosting, M.; Plantinga, T.S.; van der Meer, J.W.; Joosten, L.A.; Crevel, R.V.; 
Netea, M.G. Autophagy modulates the Mycobacterium tuberculosis-induced cytokine response. 
Immunology 2011, 134, 341?348. 
89. Lee, J.; Kim, H.R.; Quinley, C.; Kim, J.; Gonzalez-Navajas, J.; Xavier, R.; Raz, E. Autophagy 
suppresses interleukin-1beta (IL-1beta) signaling by activation of p62 degradation via lysosomal 
and proteasomal pathways. J. Biol. Chem. 2012, 287, 4033?4040. 
90. Wildenberg, M.E.; Vos, A.C.; Wolfkamp, S.C.; Duijvestein, M.; Verhaar, A.P.; Te Velde, A.A.; 
van den Brink, G.R.; Hommes, D.W. Autophagy attenuates the adaptive immune response by 
destabilizing the immunologic synapse. Gastroenterology 2012, 142, 1493?1503. 
91. Raju, D.; Hussey, S.; Ang, M.; Terebiznik, M.R.; Sibony, M.; Galindo-Mata, E.; Gupta, V.; 
Blanke, S.R.; Delgado, A.; Romero-Gallo, J.; et al. Vacuolating cytotoxin and variants in 
Atg16L1 that disrupt autophagy promote Helicobacter pylori infection in humans. Gastroenterology 
2012, 142, 1160?1171. 
92. Hwang, S.; Maloney, N.S.; Bruinsma, M.W.; Goel, G.; Duan, E.; Zhang, L.; Shrestha, B.; 
Diamond, M.S.; Dani, A.; Sosnovtsev, S.V.; et al. Nondegradative role of Atg5-Atg12/ Atg16L1 
autophagy protein complex in antiviral activity of interferon gamma. Cell Host Microbe 2012, 11, 
397?409. 
93. Bekpen, C.; Hunn, J.P.; Rohde, C.; Parvanova, I.; Guethlein, L.; Dunn, D.M.; Glowalla, E.; 
Leptin, M.; Howard, J.C. The interferon-inducible p47 (IRG) GTPases in vertebrates: Loss of  
the cell autonomous resistance mechanism in the human lineage. Genome Biol. 2005, 6, 
doi:10.1186/gb-2005-6-11-r92. 
94. Bekpen, C.; Xavier, R.J.; Eichler, E.E. Human IRGM gene ?to be or not to be?.  
Semin. Immunopathol. 2010, 32, 437?444. 
95. Nagano, Y.; Maehara, N. Induction of interferon by bacterial endotoxin. Methods Enzymol. 1981, 
78, 258?261. 
96. Collazo, C.M.; Yap, G.S.; Sempowski, G.D.; Lusby, K.C.; Tessarollo, L.; Woude, G.F.; Sher, A.; 
Taylor, G.A. Inactivation of LRG-47 and IRG-47 reveals a family of interferon gamma-inducible 
genes with essential, pathogen-specific roles in resistance to infection. J. Exp. Med. 2001, 194, 
181?188. 
97. Boehm, U.; Guethlein, L.; Klamp, T.; Ozbek, K.; Schaub, A.; Futterer, A.; Pfeffer, K.;  
Howard, J.C. Two families of GTPases dominate the complex cellular response to IFN-gamma.  
J. Immunol. 1998, 161, 6715?6723. 
98. MacMicking, J.D.; Taylor, G.A.; McKinney, J.D. Immune control of tuberculosis by  
IFN-gamma-inducible LRG-47. Science 2003, 302, 654?659. 
Cells 2012, 1 514 
 
99. Feng, C.G.; Collazo-Custodio, C.M.; Eckhaus, M.; Hieny, S.; Belkaid, Y.; Elkins, K.; Jankovic, D.; 
Taylor, G.A.; Sher, A. Mice deficient in LRG-47 display increased susceptibility to mycobacterial 
infection associated with the induction of lymphopenia. J. Immunol. 2004, 172, 1163?1168. 
100. Gutierrez, M.G.; Master, S.S.; Singh, S.B.; Taylor, G.A.; Colombo, M.I.; Deretic, V. Autophagy 
is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected 
macrophages. Cell 2004, 119, 753?766. 
101. Singh, S.B.; Davis, A.S.; Taylor, G.A.; Deretic, V. Human IRGM induces autophagy to eliminate 
intracellular mycobacteria. Science 2006, 313, 1438?1441. 
102. Gregoire, I.P.; Richetta, C.; Meyniel-Schicklin, L.; Borel, S.; Pradezynski, F.; Diaz, O.; Deloire, A.; 
Azocar, O.; Baguet, J.; Le Breton, M.; et al. IRGM is a common target of RNA viruses that 
subvert the autophagy network. PLoS Pathog. 2011, 7, e1002422. 
103. Henry, S.C.; Daniell, X.; Indaram, M.; Whitesides, J.F.; Sempowski, G.D.; Howell, D.; Oliver, T.; 
Taylor, G.A. Impaired macrophage function underscores susceptibility to Salmonella in mice 
lacking Irgm1 (LRG-47). J. Immunol. 2007, 179, 6963?6972. 
104. Butcher, B.A.; Greene, R.I.; Henry, S.C.; Annecharico, K.L.; Weinberg, J.B.; Denkers, E.Y.;  
Sher, A.; Taylor, G.A. p47 GTPases regulate Toxoplasma gondii survival in activated 
macrophages. Infect. Immun. 2005, 73, 3278?3286. 
105. Feng, C.G.; Zheng, L.; Jankovic, D.; Bafica, A.; Cannons, J.L.; Watford, W.T.; Chaussabel, D.; 
Hieny, S.; Caspar, P.; Schwartzberg, P.L.; et al. The immunity-related GTPase Irgm1 promotes 
the expansion of activated CD4+ T cell populations by preventing interferon-gamma-induced cell 
death. Nat. Immunol. 2008, 9, 1279?1287. 
106. Tsika, E.; Moore, D.J. Mechanisms of LRRK2-Mediated Neurodegeneration. Curr. Neurol. 
Neurosci. Rep. 2012, doi:10.1007/s11910-012-0265-8. 
107. Greggio, E.; Cookson, M.R. Leucine-rich repeat kinase 2 mutations and Parkinson?s disease: 
Three questions. ASN Neuro. 2009, 1, e00002. 
108. Franke, A.; McGovern, D.P.; Barrett, J.C.; Wang, K.; Radford-Smith, G.L.; Ahmad, T.; Lees, C.W.; 
Balschun, T.; Lee, J.; Roberts, R.; et al. Genome-wide meta-analysis increases to 71 the number 
of confirmed Crohn?s disease susceptibility loci. Nat. Genet. 2010, 42, 1118?1125. 
109. Biskup, S.; Moore, D.J.; Rea, A.; Lorenz-Deperieux, B.; Coombes, C.E.; Dawson, V.L.;  
Dawson, T.M.; West, A.B. Dynamic and redundant regulation of LRRK2 and LRRK1 expression. 
BMC Neurosci. 2007, 8, 102. 
110. Hakimi, M.; Selvanantham, T.; Swinton, E.; Padmore, R.F.; Tong, Y.; Kabbach, G.; Venderova, K.; 
Girardin, S.E.; Bulman, D.E.; Scherzer, C.R.; et al. Parkinson?s disease-linked LRRK2 is 
expressed in circulating and tissue immune cells and upregulated following recognition of 
microbial structures. J. Neural. Transm. 2011, 118, 795?808. 
111. Saiki, S.; Sato, S.; Hattori, N. Molecular pathogenesis of Parkinson?s disease: Update. J. Neurol. 
Neurosurg. Psychiatry 2012, 83, 430?436. 
112. Kachergus, J.; Mata, I.F.; Hulihan, M.; Taylor, J.P.; Lincoln, S.; Aasly, J.; Gibson, J.M.;  
Ross, O.A.; Lynch, T.; Wiley, J.; et al. Identification of a novel LRRK2 mutation linked to 
autosomal dominant parkinsonism: Evidence of a common founder across European populations. 
Am. J. Hum. Genet. 2005, 76, 672?680. 
Cells 2012, 1 515 
 
113. Simon-Sanchez, J.; Schulte, C.; Bras, J.M.; Sharma, M.; Gibbs, J.R.; Berg, D.; Paisan-Ruiz, C.; 
Lichtner, P.; Scholz, S.W.; Hernandez, D.G.; et al. Genome-wide association study reveals 
genetic risk underlying Parkinson?s disease. Nat. Genet. 2009, 41, 1308?1312. 
114. Satake, W.; Nakabayashi, Y.; Mizuta, I.; Hirota, Y.; Ito, C.; Kubo, M.; Kawaguchi, T.; Tsunoda, T.; 
Watanabe, M.; Takeda, A.; et al. Genome-wide association study identifies common variants at 
four loci as genetic risk factors for Parkinson?s disease. Nat. Genet. 2009, 41, 1303?1307. 
115. Cheung, Z.H.; Ip, N.Y. Autophagy deregulation in neurodegenerative diseases?Recent advances 
and future perspectives. J. Neurochem. 2011, 118, 317?325. 
116. Alegre-Abarrategui, J.; Christian, H.; Lufino, M.M.; Mutihac, R.; Venda, L.L.; Ansorge, O.; 
Wade-Martins, R. LRRK2 regulates autophagic activity and localizes to specific membrane 
microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 2009, 18, 
4022?4034. 
117. Higashi, S.; Moore, D.J.; Yamamoto, R.; Minegishi, M.; Sato, K.; Togo, T.; Katsuse, O.; 
Uchikado, H.; Furukawa, Y.; Hino, H.; et al. Abnormal localization of leucine-rich repeat kinase 2 
to the endosomal-lysosomal compartment in lewy body disease. J. Neuropathol. Exp. Neurol. 
2009, 68, 994?1005. 
118. Alegre-Abarrategui, J.; Wade-Martins, R. Parkinson disease, LRRK2 and the endocytic-autophagic 
pathway. Autophagy 2009, 5, 1208?1210. 
119. Gomez-Suaga, P.; Luzon-Toro, B.; Churamani, D.; Zhang, L.; Bloor-Young, D.; Patel, S.; 
Woodman, P.G.; Churchill, G.C.; Hilfiker, S. Leucine-rich repeat kinase 2 regulates autophagy 
through a calcium-dependent pathway involving NAADP. Hum. Mol. Genet. 2012, 21, 511?525. 
120. Sanchez-Danes, A.; Richaud-Patin, Y.; Carballo-Carbajal, I.; Jimenez-Delgado, S.; Caig, C.; 
Mora, S.; Di Guglielmo, C.; Ezquerra, M.; Patel, B.; Giralt, A.; et al. Disease-specific phenotypes 
in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson?s disease. 
EMBO Mol. Med. 2012, 4, 380?395. 
121. Tong, Y.; Yamaguchi, H.; Giaime, E.; Boyle, S.; Kopan, R.; Kelleher, R.J., 3rd; Shen, J. Loss of 
leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of 
alpha-synuclein, and apoptotic cell death in aged mice. Proc. Natl. Acad. Sci. USA 2010, 107, 
9879?9884. 
122. Liu, Z.; Lee, J.; Krummey, S.; Lu, W.; Cai, H.; Lenardo, M.J. The kinase LRRK2 is a regulator of 
the transcription factor NFAT that modulates the severity of inflammatory bowel disease.  
Nat. Immunol. 2011, 12, 1063?1070. 
123. Gardet, A.; Benita, Y.; Li, C.; Sands, B.E.; Ballester, I.; Stevens, C.; Korzenik, J.R.; Rioux, J.D.; 
Daly, M.J.; Xavier, R.J.; et al. LRRK2 is involved in the IFN-gamma response and host response 
to pathogens. J. Immunol. 2010, 185, 5577?5585. 
124. Man, S.M.; Kaakoush, N.O.; Mitchell, H.M. The role of bacteria and pattern-recognition 
receptors in Crohn?s disease. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 152?168. 
125. Jackson, M.D.; Denu, J.M. Molecular reactions of protein phosphatases?Insights from structure 
and chemistry. Chem. Rev. 2001, 101, 2313?2340. 
126. Robinson, F.L.; Dixon, J.E. Myotubularin phosphatases: Policing 3-phosphoinositides.  
Trends Cell Biol. 2006, 16, 403?412. 
Cells 2012, 1 516 
 
127. Vergne, I.; Deretic, V. The role of PI3P phosphatases in the regulation of autophagy. FEBS Lett. 
2010, 584, 1313?1318. 
128. Obara, K.; Noda, T.; Niimi, K.; Ohsumi, Y. Transport of phosphatidylinositol 3-phosphate into the 
vacuole via autophagic membranes in Saccharomyces cerevisiae. Genes Cells 2008, 13, 537?547. 
129. Zhao, R.; Qi, Y.; Chen, J.; Zhao, Z.J. FYVE-DSP2, a FYVE domain-containing dual specificity 
protein phosphatase that dephosphorylates phosphotidylinositol 3-phosphate. Exp. Cell Res. 2001, 
265, 329?338. 
130. Walker, D.M.; Urbe, S.; Dove, S.K.; Tenza, D.; Raposo, G.; Clague, M.J. Characterization of 
MTMR3. an inositol lipid 3-phosphatase with novel substrate specificity. Curr. Biol. 2001, 11, 
1600?1605. 
131. Taguchi-Atarashi, N.; Hamasaki, M.; Matsunaga, K.; Omori, H.; Ktistakis, N.T.; Yoshimori, T.; 
Noda, T. Modulation of local PtdIns3P levels by the PI phosphatase MTMR3 regulates 
constitutive autophagy. Traffic 2010, 11, 468?478. 
132. Blommaart, E.F.; Krause, U.; Schellens, J.P.; Vreeling-Sindelarova, H.; Meijer, A.J. The 
phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated 
rat hepatocytes. Eur. J. Biochem. 1997, 243, 240?246. 
133. Dove, S.K.; Piper, R.C.; McEwen, R.K.; Yu, J.W.; King, M.C.; Hughes, D.C.; Thuring, J.; 
Holmes, A.B.; Cooke, F.T.; Michell, R.H.; et al. Svp1p defines a family of phosphatidylinositol 
3,5-bisphosphate effectors. EMBO J. 2004, 23, 1922?1933. 
134. Stromhaug, P.E.; Reggiori, F.; Guan, J.; Wang, C.W.; Klionsky, D.J. Atg21 is a phosphoinositide 
binding protein required for efficient lipidation and localization of Atg8 during uptake of 
aminopeptidase I by selective autophagy. Mol. Biol. Cell 2004, 15, 3553?3566. 
135. Krick, R.; Tolstrup, J.; Appelles, A.; Henke, S.; Thumm, M. The relevance of the 
phosphatidylinositolphosphat-binding motif FRRGT of Atg18 and Atg21 for the Cvt pathway and 
autophagy. FEBS Lett. 2006, 580, 4632?4638. 
136. Obara, K.; Ohsumi, Y. Dynamics and function of PtdIns(3)P in autophagy. Autophagy 2008, 4, 
952?954. 
137. Levine, B.; Deretic, V. Unveiling the roles of autophagy in innate and adaptive immunity.  
Nat. Rev. Immunol. 2007, 7, 767?777. 
138. Hu, Z.; Wu, C.; Shi, Y.; Guo, H.; Zhao, X.; Yin, Z.; Yang, L.; Dai, J.; Hu, L.; Tan, W.; et al. A 
genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 
22q12.2 in Han Chinese. Nat. Genet. 2011, 43, 792?796. 
139. Song, S.Y.; Kang, M.R.; Yoo, N.J.; Lee, S.H. Mutational analysis of mononucleotide repeats in 
dual specificity tyrosine phosphatase genes in gastric and colon carcinomas with microsatellite 
instability. APMIS 2010, 118, 389?393. 
140. Kimmelman, A.C. The dynamic nature of autophagy in cancer. Genes Dev. 2011, 25, 1999?2010. 
141. Doody, K.M.; Bourdeau, A.; Tremblay, M.L. T-cell protein tyrosine phosphatase is a key 
regulator in immune cell signaling: Lessons from the knockout mouse model and implications in 
human disease. Immunol. Rev. 2009, 228, 325?341. 
Cells 2012, 1 517 
 
142. Cool, D.E.; Tonks, N.K.; Charbonneau, H.; Walsh, K.A.; Fischer, E.H.; Krebs, E.G. cDNA 
isolated from a human T-cell library encodes a member of the protein-tyrosine-phosphatase family. 
Proc. Natl. Acad. Sci. U. S. A. 1989, 86, 5257?5261. 
143. Heinonen, K.M.; Nestel, F.P.; Newell, E.W.; Charette, G.; Seemayer, T.A.; Tremblay, M.L.;  
Lapp, W.S. T-cell protein tyrosine phosphatase deletion results in progressive systemic 
inflammatory disease. Blood 2004, 103, 3457?3464. 
144. Scharl, M.; Paul, G.; Weber, A.; Jung, B.C.; Docherty, M.J.; Hausmann, M.; Rogler, G.;  
Barrett, K.E.; McCole, D.F. Protection of epithelial barrier function by the Crohn?s disease 
associated gene protein tyrosine phosphatase N2. Gastroenterology 2009, 137, 2030?2040. 
145. Scharl, M.; Hruz, P.; McCole, D.F. Protein tyrosine phosphatase non-receptor Type 2 regulates 
IFN-gamma-induced cytokine signaling in THP-1 monocytes. Inflamm. Bowel Dis. 2010, 16, 
2055?2064. 
146. Scharl, M.; McCole, D.F.; Weber, A.; Vavricka, S.R.; Frei, P.; Kellermeier, S.; Pesch, T.;  
Fried, M.; Rogler, G. Protein tyrosine phosphatase N2 regulates TNFalpha-induced signalling and 
cytokine secretion in human intestinal epithelial cells. Gut 2011, 60, 189?197. 
147. Scharl, M.; Wojtal, K.A.; Becker, H.M.; Fischbeck, A.; Frei, P.; Arikkat, J.; Pesch, T.; 
Kellermeier, S.; Boone, D.L.; Weber, A.; et al. Protein tyrosine phosphatase nonreceptor type 2 
regulates autophagosome formation in human intestinal cells. Inflamm. Bowel Dis. 2011, 
doi:10.1002/ibd.21891. 
148. Scharl, M.; Mwinyi, J.; Fischbeck, A.; Leucht, K.; Eloranta, J.J.; Arikkat, J.; Pesch, T.; 
Kellermeier, S.; Mair, A.; Kullak-Ublick, G.A.; et al. Crohn?s disease-associated polymorphism 
within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy. 
Inflamm. Bowel Dis. 2012, 18, 900?912. 
149. Amre, D.K.; Mack, D.R.; Israel, D.; Krupoves, A.; Costea, I.; Lambrette, P.; Grimard, G.; Dong, J.; 
Levy, E. NELL1, NCF4, and FAM92B genes are not major susceptibility genes for Crohn?s 
disease in Canadian children and young adults. Inflamm. Bowel Dis. 2012, 18, 529?535. 
150. Honbou, K.; Minakami, R.; Yuzawa, S.; Takeya, R.; Suzuki, N.N.; Kamakura, S.; Sumimoto, H.; 
Inagaki, F. Full-length p40phox structure suggests a basis for regulation mechanism of its 
membrane binding. EMBO J. 2007, 26, 1176?1186. 
151. Ellson, C.D.; Davidson, K.; Ferguson, G.J.; O?Connor, R.; Stephens, L.R.; Hawkins, P.T. 
Neutrophils from p40phox-/- mice exhibit severe defects in NADPH oxidase regulation and 
oxidant-dependent bacterial killing. J. Exp. Med. 2006, 203, 1927?1937. 
152. Scherz-Shouval, R.; Shvets, E.; Fass, E.; Shorer, H.; Gil, L.; Elazar, Z. Reactive oxygen species 
are essential for autophagy and specifically regulate the activity of Atg4. EMBO J. 2007, 26, 
1749?1760. 
153. Muise, A.M.; Xu, W.; Guo, C.H.; Walters, T.D.; Wolters, V.M.; Fattouh, R.; Lam, G.Y.; Hu, P.; 
Murchie, R.; Sherlock, M.; et al. NADPH oxidase complex and IBD candidate gene studies: 
Identification of a rare variant in NCF2 that results in reduced binding to RAC2. Gut 2012, 61, 
1028?1035. 
Cells 2012, 1 518 
 
154. Eglinton, T.W.; Roberts, R.; Pearson, J.; Barclay, M.; Merriman, T.R.; Frizelle, F.A.; Gearry, R.B. 
Clinical and genetic risk factors for perianal Crohn?s disease in a population-based cohort. Am. J. 
Gastroenterol. 2012, 107, 589?596. 
155. Somasundaram, R.; Deuring, J.J.; van der Woude, C.J.; Peppelenbosch, M.P.; Fuhler, G.M. 
Linking risk conferring mutations in NCF4 to functional consequences in Crohn?s disease.  
Gut 2012, 61, 1097. 
156. Alers, S.; Loffler, A.S.; Wesselborg, S.; Stork, B. Role of AMPK-mTOR-Ulk1/2 in the regulation 
of autophagy: Cross talk, shortcuts, and feedbacks. Mol. Cell Biol. 2012, 32, 2?11. 
157. Alers, S.; Loffler, A.S.; Wesselborg, S.; Stork, B. The incredible ULKs. Cell Commun. Signal. 
2012, 10, 7. 
158. Croxen, M.A.; Finlay, B.B. Molecular mechanisms of E. coli pathogenicity. Nat. Rev. Microbiol. 
2010, 8, 26?38. 
159. Darfeuille-Michaud, A.; Neut, C.; Barnich, N.; Lederman, E.; Di Martino, P.; Desreumaux, P.; 
Gambiez, L.; Joly, B.; Cortot, A.; Colombel, J.F. Presence of adherent E. coli strains in ileal 
mucosa of patients with Crohn?s disease. Gastroenterology 1998, 115, 1405?1413. 
160. Boudeau, J.; Glasser, A.L.; Masseret, E.; Joly, B.; Darfeuille-Michaud, A. Invasive ability of an  
E. coli strain isolated from the ileal mucosa of a patient with Crohn?s disease. Infect. Immun. 
1999, 67, 4499?4509. 
161. Sepehri, S.; Khafipour, E.; Bernstein, C.N.; Coombes, B.K.; Pilar, A.V.; Karmali, M.; Ziebell, K.; 
Krause, D.O. Characterization of E. coli isolated from gut biopsies of newly diagnosed patients 
with inflammatory bowel disease. Inflamm. Bowel Dis. 2011, 17, 1451?1463. 
162. Barnich, N.; Carvalho, F.A.; Glasser, A.L.; Darcha, C.; Jantscheff, P.; Allez, M.; Peeters, H.; 
Bommelaer, G.; Desreumaux, P.; Colombel, J.F.; et al. CEACAM6 acts as a receptor for 
adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J. Clin. Invest. 
2007, 117, 1566?1574. 
163. Rolhion, N.; Barnich, N.; Bringer, M.A.; Glasser, A.L.; Ranc, J.; Hebuterne, X.; Hofman, P.; 
Darfeuille-Michaud, A. Abnormally expressed ER stress response chaperone Gp96 in CD favours 
adherent-invasive E. coli invasion. Gut 2010, 59, 1355?1362. 
164. Miquel, S.; Peyretaillade, E.; Claret, L.; de Vallee, A.; Dossat, C.; Vacherie, B.; Zineb, E.H.; 
Segurens, B.; Barbe, V.; Sauvanet, P.; et al. Complete genome sequence of Crohn?s  
disease-associated adherent-invasive E. coli strain LF82. PLoS One 2010, 5, e12714. 
165. Chassaing, B.; Rolhion, N.; de Vallee, A.; Salim, S.Y.; Prorok-Hamon, M.; Neut, C.; Campbell, B.J.; 
Soderholm, J.D.; Hugot, J.P.; Colombel, J.F.; et al. Crohn disease?associated adherent-invasive  
E. coli bacteria target mouse and human Peyer?s patches via long polar fimbriae. J. Clin. Invest. 
2011, 121, 966?975. 
166. Lapaquette, P.; Glasser, A.L.; Huett, A.; Xavier, R.J.; Darfeuille-Michaud, A. Crohn?s  
disease-associated adherent-invasive E. coli are selectively favoured by impaired autophagy to 
replicate intracellularly. Cell Microbiol. 2010, 12, 99?113. 
167. Lapaquette, P.; Bringer, M.A.; Darfeuille-Michaud, A. Defects in autophagy favour adherent-invasive 
E. coli persistence within macrophages leading to increased pro-inflammatory response.  
Cell Microbiol. 2012, 14, 791?807. 
Cells 2012, 1 519 
 
168. Brest, P.; Lapaquette, P.; Souidi, M.; Lebrigand, K.; Cesaro, A.; Vouret-Craviari, V.; Mari, B.; 
Barbry, P.; Mosnier, J.F.; Hebuterne, X.; et al. A synonymous variant in IRGM alters a binding 
site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn?s disease.  
Nat. Genet. 2011, 43, 242?245. 
169. Fowler, E.V.; Doecke, J.; Simms, L.A.; Zhao, Z.Z.; Webb, P.M.; Hayward, N.K.; Whiteman, D.C.; 
Florin, T.H.; Montgomery, G.W.; Cavanaugh, J.A.; et al. ATG16L1 T300A shows strong 
associations with disease subgroups in a large Australian IBD population: Further support for 
significant disease heterogeneity. Am. J. Gastroenterol. 2008, 103, 2519?2526. 
170. Lauriola, M.; Ugolini, G.; Rivetti, S.; Nani, S.; Rosati, G.; Zanotti, S.; Montroni, I.; Manaresi, A.; 
Zattoni, D.; Belluzzi, A.; et al. IL23R, NOD2/CARD15, ATG16L1 and PHOX2B polymorphisms 
in a group of patients with Crohn?s disease and correlation with sub-phenotypes. Int. J. Mol. Med. 
2011, 27, 469?477. 
171. Sehgal, R.; Berg, A.; Polinski, J.I.; Hegarty, J.P.; Lin, Z.; McKenna, K.J.; Stewart, D.B.; Poritz, L.S.; 
Koltun, W.A. Mutations in IRGM are associated with more frequent need for surgery in patients 
with ileocolonic Crohn?s disease. Dis. Colon Rectum 2012, 55, 115?121. 
172. Simillis, C.; Jacovides, M.; Reese, G.E.; Yamamoto, T.; Tekkis, P.P. Meta-analysis of the role of 
granulomas in the recurrence of Crohn disease. Dis. Colon Rectum 2010, 53, 177?185. 
173. Wolfkamp, S.C.; Te Velde, A.A.; Weersma, R.K.; Ponsioen, C.Y.; Stokkers, P.C. Is there a role 
for ????????disease-associated autophagy genes ATG16L1 and IRGM in formation of granulomas? 
Eur. J. Gastroenterol. Hepatol. 2010, 22, 933?937. 
174. Mazor, Y.; Karban, A.; Nesher, S.; Weiss, B.; Leshinsky-Silver, E.; Levine, A.; Eliakim, R. 
Granulomas in Crohn?s disease: Are newly discovered genetic variants involved? J. Crohn?s 
Colitis 2010, 4, 438?443. 
175. Brinar, M.; Vermeire, S.; Cleynen, I.; Lemmens, B.; Sagaert, X.; Henckaerts, L.; van Assche, G.; 
Geboes, K.; Rutgeerts, P.; de Hertogh, G. Genetic variants in autophagy-related genes and 
granuloma formation in a cohort of surgically treated Crohn?s disease patients. J. Crohn?s Colitis 
2012, 6, 43?50. 
176. Murdoch, T.B.; Xu, W.; Stempak, J.M.; Landers, C.; Targan, S.R.; Rotter, J.I.; Silverberg, M.S. 
Pattern recognition receptor and autophagy gene variants are associated with development of 
antimicrobial antibodies in Crohn?s disease. Inflamm. Bowel Dis. 2012, doi:10.1002/ibd.22884. 
177. Frank, D.N.; Robertson, C.E.; Hamm, C.M.; Kpadeh, Z.; Zhang, T.; Chen, H.; Zhu, W.; Sartor, R.B.; 
Boedeker, E.C.; Harpaz, N.; et al. Disease phenotype and genotype are associated with shifts in 
intestinal-associated microbiota in inflammatory bowel diseases. Inflamm. Bowel Dis. 2011, 17, 
179?184. 
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
